Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Equity Average (2022 - 2025)

Taysha Gene Therapies' Equity Average history spans 4 years, with the latest figure at $233.9 million for Q3 2025.

  • For Q3 2025, Equity Average rose 136.62% year-over-year to $233.9 million; the TTM value through Sep 2025 reached $233.9 million, up 136.62%, while the annual FY2024 figure was $73.2 million, 93.0% up from the prior year.
  • Equity Average for Q3 2025 was $233.9 million at Taysha Gene Therapies, up from $151.9 million in the prior quarter.
  • Across five years, Equity Average topped out at $233.9 million in Q3 2025 and bottomed at -$43.1 million in Q3 2023.
  • The 4-year median for Equity Average is $52.5 million (2022), against an average of $55.7 million.
  • The largest annual shift saw Equity Average crashed 299.56% in 2023 before it skyrocketed 1019.97% in 2024.
  • A 4-year view of Equity Average shows it stood at $5.8 million in 2022, then skyrocketed by 121.62% to $12.9 million in 2023, then surged by 520.85% to $80.2 million in 2024, then surged by 191.74% to $233.9 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Equity Average are $233.9 million (Q3 2025), $151.9 million (Q2 2025), and $63.3 million (Q1 2025).